Andreikos D, Spandidos D, Georgakopoulou V
Int J Oncol. 2025; 66(3).
PMID: 39981889
PMC: 11844339.
DOI: 10.3892/ijo.2025.5729.
Salvado A, Capone L, Zamorano P, Samudio M, Garcia-de-Davila M, Ernst G
Rev Bras Med Trab. 2025; 22(4):e20241271.
PMID: 39958414
PMC: 11822978.
DOI: 10.47626/1679-4435-2024-1271.
Karunakaran K, Ganapathiraju M
BJC Rep. 2024; 2(1):42.
PMID: 39516360
PMC: 11524009.
DOI: 10.1038/s44276-024-00062-w.
Arabi T, Alkattan W, Osman N, Sabbah B, Ashraf N, Ouban A
Front Oncol. 2024; 14:1435535.
PMID: 39364319
PMC: 11446878.
DOI: 10.3389/fonc.2024.1435535.
Van den Bossche J, De Laere M, Deschepper K, Germonpre P, Valcke Y, Lamont J
PLoS One. 2024; 19(7):e0307204.
PMID: 39008481
PMC: 11249236.
DOI: 10.1371/journal.pone.0307204.
[Advances in Targeted Therapy for Malignant Pleural Mesothelioma].
Fu F, Zhang Y, Shen H
Zhongguo Fei Ai Za Zhi. 2024; 27(5):391-398.
PMID: 38880927
PMC: 11183316.
DOI: 10.3779/j.issn.1009-3419.2024.102.18.
Serum Levels of N- and C-ERC/Mesothelin and Clinicopathological Factors in Mesothelioma Patients and Those without Mesothelioma.
Koyanagi A, Kajino K, Nojiri S, Abe M, Kobayashi T, Sugitani Y
Juntendo Iji Zasshi. 2024; 69(2):124-136.
PMID: 38854453
PMC: 11153076.
DOI: 10.14789/jmj.JMJ22-0042-OA.
Comprehensive genomic profiling of pediatric peritoneal mesothelioma: case report with a literature review.
Redzepagic J, Zvizdic Z, Bilalovic N, Milisic E, Bukvic M, Vranic S
J Surg Case Rep. 2024; 2024(5):rjae324.
PMID: 38764730
PMC: 11102791.
DOI: 10.1093/jscr/rjae324.
The MexTAg collaborative cross: host genetics affects asbestos related disease latency, but has little influence once tumours develop.
Fisher S, Patrick K, Hoang T, Marcq E, Behrouzfar K, Young S
Front Toxicol. 2024; 6:1373003.
PMID: 38694815
PMC: 11061428.
DOI: 10.3389/ftox.2024.1373003.
Diagnosis and treatment of malignant retroperitoneal mesothelioma: A case report.
Tang F, Cui Y, Gao Y
Medicine (Baltimore). 2024; 103(17):e37985.
PMID: 38669368
PMC: 11049770.
DOI: 10.1097/MD.0000000000037985.
Pleural mesothelioma (PMe): The evolving molecular knowledge of a rare and aggressive cancer.
Rigon M, Mutti L, Campanella M
Mol Oncol. 2024; 18(4):797-814.
PMID: 38459714
PMC: 10994233.
DOI: 10.1002/1878-0261.13591.
The lncRNAs Gas5, MALAT1 and SNHG8 as diagnostic biomarkers for epithelial malignant pleural mesothelioma in Egyptian patients.
Elkahwagy D, Kiriacos C, Sobeih M, Khorshid O, Mansour M
Sci Rep. 2024; 14(1):4823.
PMID: 38413635
PMC: 10899637.
DOI: 10.1038/s41598-024-55083-9.
Validation of a Gene Expression Approach for the Cytological Diagnosis of Epithelioid and Biphasic Pleural Mesothelioma on a Consecutive Series.
Bruno R, Poma A, Ali G, Proietti A, Ribechini A, Chella A
Cancers (Basel). 2023; 15(23).
PMID: 38067238
PMC: 10705177.
DOI: 10.3390/cancers15235534.
Combined Inhibition of EZH2 and FGFR is Synergistic in BAP1-deficient Malignant Mesothelioma.
Badhai J, Landman N, Pandey G, Song J, Hulsman D, Krijgsman O
Cancer Res Commun. 2023; 4(1):18-27.
PMID: 38054839
PMC: 10763530.
DOI: 10.1158/2767-9764.CRC-23-0276.
: a promising vector for tumor immunotherapy.
Ding Y, Shu L, He R, Chen K, Deng Y, Zhou Z
Front Immunol. 2023; 14:1278011.
PMID: 37868979
PMC: 10587691.
DOI: 10.3389/fimmu.2023.1278011.
Malignant Peritoneal Mesothelioma: An In-Depth and Up-to-Date Review of Pathogenesis, Diagnosis, Management and Future Directions.
Karpes J, Shamavonian R, Dewhurst S, Cheng E, Wijayawardana R, Ahmadi N
Cancers (Basel). 2023; 15(19).
PMID: 37835398
PMC: 10571654.
DOI: 10.3390/cancers15194704.
Comprehensive bioinformatics analysis of the role of VWF in the tumor microenvironment of malignant mesothelioma.
Weng J, Chen J
Medicine (Baltimore). 2023; 102(41):e35579.
PMID: 37832118
PMC: 10578691.
DOI: 10.1097/MD.0000000000035579.
REDCap and the National Mesothelioma Virtual Bank-a scalable and sustainable model for rare disease biorepositories.
Rashid R, Copelli S, Silverstein J, Becich M
J Am Med Inform Assoc. 2023; 30(10):1634-1644.
PMID: 37487555
PMC: 10531116.
DOI: 10.1093/jamia/ocad132.
Tips and Tricks in Thoracic Radiology for Beginners: A Findings-Based Approach.
Borgheresi A, Agostini A, Pierpaoli L, Bruno A, Valeri T, Danti G
Tomography. 2023; 9(3):1153-1186.
PMID: 37368547
PMC: 10301342.
DOI: 10.3390/tomography9030095.
Geldanamycin treatment does not result in anti-cancer activity in a preclinical model of orthotopic mesothelioma.
Orozco Morales M, Rinaldi C, de Jong E, Lansley S, Lee Y, Zemek R
PLoS One. 2023; 18(5):e0274364.
PMID: 37146029
PMC: 10162533.
DOI: 10.1371/journal.pone.0274364.
